A 2011 repot has shown that use of diabetes drug Duetact® (glimepiride and pioglitazone), manufactured by Takeda Pharmaceuticals is associated with a dramatically-increased risk of bladder cancer. Duetact®, a drug that works by increasing the body’s sensitivity to insulin, contains two chemicals proven to be carcinogenic: sulfonylurea and pioglitazone. Sulfonylurea has been previously linked to
Duetact
Duetact Linked to Risk for Cancer and Major Cardiac Events
By Staff on
Posted in Duetact
Recently, an ingredient in Duetact®, a popular Type-II diabetes drug, has been found to be associated with an increased risk for bladder cancer. While another research team (Piccinni et al, 2011) published a report linking pioglitazone to bladder cancer, this report, titled “Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies…